Best Chemotherapy hematologist-oncologists in Turkey: TOP 47 doctors

Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the (Transplant) Unit for 13 years in (unrelated and intrafamilial), (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.

MEDICAL AREAS OF INTEREST

Healthy baby follow-up and vaccinations

Lymph node enlargement

Pediatric patients with anemia (anemia)

Leukemia

Lymphoma

Transplant

ITP

Thalassemias

Hemophiliacs

Solid tumors

Hemangioma

Childhood blood disorders

Children with frequent infections

Fever of unknown origin

Malnutrition in children

Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Center.
Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.

MEDICAL INTERESTS

• Leukemia
• Lymphoma
• Multiple myeloma
• Anemia
• Bleeding and coagulation disorders
• Hemophilia

Education

• Ege Faculty of Medicine 1978
• Specialization in Pediatrics 1982
• Subspecialty Pediatric Oncology 2002 (EU Faculty of Medicine)
• Pediatric Hematology and Oncology 2012 (EU Faculty of Medicine)
• Deputy Chief of Clinic 1988 Tepecik EAH
• Clinical Chief 1993 Tepecik EAH
• Associate Professorship 1995
• Professorship  2002
• Ege U. Faculty of Medicine, faculty member 1998 – 2022
• EU Faculty of Medicine Department of Pediatrics 2009-2018
• Member of Tepecik Education Planning and Coordination Board (1993-1998)
• SSI Tepecik Hospital Ethics Committee Chairman (1996-1998)
• Turkish Society of Pediatric Hematology " Working Group Co-Chair" (2002-2006)
• Turkish Society of Pediatric Hematology " Working Group" (2006-2008)
• Turkish Society of Pediatric Hematology - Responsible for "Online" Data Registry Sy 2007-ongoing.
• Ege University Regenerative Medicine and Cell Commission Chairman, 2011-2021

Institutional Memberships

• Turkish Medical Association İzmir and Kocaeli Branch
• Turkish National Pediatric Association - İzmir
• European Group for (E); Ege University Pediatric Unit was accredited by the European Group for (E) in June 2007.
• Turkish Society of Pediatric Hematology - Board Member for two terms (2005-2009)
• Turkish Society of Hematology - Board Member for two terms (2001/2005)
• Turkish Pediatric Oncology Association
• Foundation (KITVAK) Member of the Board of Trustees

Units he is the founder of                        

1- SSI Tepecik Hospital Pediatric Oncology Clinic (1990) 
2- SSI Tepecik Hospital Pediatric Unit (1992) 
3- EU Faculty of Medicine Pediatric Unit (1998) 
4- FOUNDER of JOURNAL OF PEDIATRIC RESEARCH, 2014; SCI application was made in 2022.  

Transplantation units that he contributed to the establishment of                        

1. İzmir BUÇH EAH Pediatric Unit (2019) 
2. Ümraniye EAH Pediatric Unit (2020) 
3. Kanuni Sultan Süleyman EAH Pediatric Unit (2020) (Transferred to Çam Sakura EAH)

Awards

• Thrombotic parameters in transplant patients, Pediatric Hematology Congress, Trabzon 2003
• CD133 Antigen in Cell: Pediatric Hematology Congress 2005. Research award
• The role of Toll like receptors in febrile neutropenic patients, Best poster award. Turkish Hematology Congress 2008, Çeşme-İzmir
• National pediatric transplantation activity- Oral presentation second prize, Turkish Hematology Society Cell Transplantation Congress, 2022, Antalya

Publications

Kansoy S. " and Cell Transplantation Child Health and Diseases, 1st edition, EU Faculty of Medicine Printing House, 1999, İzmir

Kansoy S. in Thalassemia Major III. Aegean Thalassemia Days Book, 2000, Izmir

Kansoy S. Pediatric KIT Center Standards in Turkey. Childhood Acute Leukemias, Antalya 2000: 73-5

Kansoy S. Late Side Effects in Children. Special issue of Journal of Turkish Clinics. 2003

Kansoy S. Cell Applications in and Cell Transplantation. Pediatric Oncology Nursing Course Book, İzmir, 2005

Kansoy S. Cord Blood as a Cell Source. Cell Special Issue. Turkey Clinics, 2008

Kansoy S. Cell Transplantation in Lymphomas. General Pediatrics Book, Ed. Prof.Dr.Enver Hasanoglu, 2009

Kansoy S, Aksoylar S. in Children. Pediatrics, 2014 and 2017

Kansoy S. Rhabdomyosarcoma. Pediatrics, 2014 and 2017

Kansoy S. Approach to the child with cancer according to clinical findings. Pediatrics, 2014 and 2017 

11. Çetingül N, S.Kansoy, M.Kantar. Oncological Diseases. Pediatrics (Ed. A. Cura), 641-672, Ege University Print house, İzmir, 1999.  (1.05 points)

Kansoy S, M.Kantar. Head, Face and Eye Examination. Pediatric Prosthetic Physical Examination and Symptom Information (Ed. A.Cura)

Kantar M. Metabolic Emergency Problems in Oncology. Oncologic Emergencies and Supportive Care in Childhood (Ed. N. Çetingül, S. Kansoy), 15-24, Meta Basım, İzmir, 2003. 

Cord Blood Transplants in Turkey. HEMATOLOGIST, 2016

Kansoy S. Central Nervous Sy Tumors in Children Pediatrics, 2014 and 2017

Acute myeloblastic leukemia in children and its treatment. Pediatric Oncology Textbook, Poplack's Turkish, 2020

National pediatric transplant activity, 2020

Childhood transplantation indications, Turkey Clinics - International book 2020

In addition to the studies and papers in international journals published in large numbers, he is involved in international multicenter studies in some journals with high impact value.

Prof. Şeref Kömürcü is an ECFMG and ESMO-certified medical and breast oncologist with over 20 years of experience. He specializes in solid cancer, breast cancer, colorectal and lung cancer treatment and has held teaching and scientific positions throughout his career. He is a member of several professional organizations.

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Education and Expertise

Selcuk University Meram Faculty of Medicine - Medical Education

Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

Experience

Malatya State Hospital Internal Diseases Clinic

Ankara Oncology Hospital Medical Oncology Clinic

Erzurum Regional Training and Research Hospital Medical Oncology Clinic


AREAS OF INTEREST

Lung cancer

esophageal cancer

Gastric cancer

breast cancer

Gastrointestinal surgery

https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

Present
Istanbul Florence Nightingale Hospital
Medical Oncology

2022-2024
Memorial Şişli Hospital
Medical Oncology Specialist

2021-2022
Institut Jules Bordet
Clinical Research Fellowship

2020-2022
Marmara University Pendik Training and Research Hospital
Medical Oncology Specialist

2019-2019
Institut Jules Bordet
Clinical Research Fellowship

2016-2019
Marmara University Faculty of Medicine, Department of Medical Oncology
Medical Oncology Fellowship

2014-2016
Golbasi Public Hospital
Internal Medicine Specialist

2013-2014
MD Anderson Cancer Center
Observership

2013
Bellvitge Hospital, Barcelona, Spain
Observership

2009 -2014
Hacettepe University Faculty of Medicine
Internal Medicine Residency

Pediatric Hematology and Oncology / Pediatric Oncology

AREAS OF INTEREST

• Breast cancer
• Colon cancer
• Lung cancer
• Malignant melanoma
• Urogenital cancers
• Gynecological cancers
• Digestive sy cancers

Education and Specialization

• 1987-1993 BSc Faculty of Medicine, Uludağ University Faculty of Medicine
• 1994-1999 BSc Internal Medicine Ondokuz Mayıs University Faculty of Medicine
• 2008-2011 PhD Medical Oncology Ankara Numune Training and Research Hospital
• 2016 Assoc. Prof. / Prof. Dr. Medical Oncology Okmeydanı Training and Research Hospital

Experience

• 1993-1994 General Practitioner Senirkent State Hospital Senirkent, Isparta
• 1994-1999 Research Position Ondokuz Mayıs University Faculty of Medicine Internal Medicine Department, Samsun
• 2000-2006 Specialist Doctor Diyarbakır SSK Hospital, Diyarbakır
• 2006-2008 Specialist Doctor Diyarbakır State Hospital, Diyarbakır
• 2008-2011 Dr. Minor Assistant Ankara Numune Training and Research Hospital
• 2011-2013 Specialist Doctor Diyarbakır Training and Research Hospital, Medical Oncology
• 2013- 2016 Specialist Doctor Okmeydanı Training and Research Hospital, Medical Oncology Clinic
• 2016 Education Manager Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Assoc. Prof.

Professional Memberships

Turkish Society of Medical Oncology

Education and Training:

• Medical Degree: Graduated from Uludağ University Faculty of Medicine in 1993.
• Specialization in Internal Medicine: Completed at Ondokuz Mayıs University Faculty of Medicine in 1999.
• Medical Oncology Fellowship: Completed at Ankara Numune Research and Training Hospital in 2011.
•  
• Professional Experience:
• Isparta Senirkent State Hospital: Completed his mandatory service as an Internal Medicine Specialist and Hemodialysis Responsible Physician (1993-1994).
• Prof. Dr. Gazi Yaşargil Training and Research Hospital: Served as a Medical Oncologist (2011-2013).
• Okmeydanı Research and Training Hospital: Achieved the title of Associate Professor and later full Professor, significantly contributing to medical oncology (2013-2016).
• Current Position: Professor of Medical Oncology at İstinye University Hospital Medical Park Gaziosmanpaşa, Istanbul, where he continues to provide top-tier oncology care and mentorship.

Areas of Expertise:

• Cancer Treatment: Specializes in the treatment of various cancers, including breast, colon, lung, malignant melanoma, urogenital, gynecological, and gastrointestinal cancers.
• Advanced Therapies: Proficient in administering chemotherapy, immunotherapy, and other cutting-edge treatments for cancer patients.
• Research and Education: Actively involved in cancer research and dedicated to educating the next generation of oncologists, continuously enhancing the field through both clinical practice and academic contributions.

• Extensive Experience:
•  
• With over 24 years of medical practice, Prof. Dr. Cihan is a highly respected figure in oncology, known for his comprehensive approach to cancer treatment.
• International Recognition: Participates in numerous international seminars and congresses, keeping abreast of the latest advancements in oncology.
• Patient-Centric Care: Renowned for his compassionate and personalized approach to patient care, ensuring tailored treatment plans that address the unique needs of each patient.
• Multidisciplinary Collaboration: Works with a multidisciplinary team of experts at Medical Park, providing holistic and coordinated care to achieve the best possible outcomes for patients.

Achievements and Awards:

• Academic Contributions: Has contributed significantly to oncology literature and research, with numerous publications in reputable medical journals.
• Leadership in Oncology: Recognized for his leadership in oncology, both in clinical settings and academic institutions, influencing cancer treatment practices and policies.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Syic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Syic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing Sy (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Education & Expertise

• 1997 | Hacettepe University Faculty of Medicine – Medical Degree
• 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
• 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

Professional Experience

• 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
• 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
• 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
• 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
• 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Transplant Center, Gebze
• 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

Courses & Certifications

• and Cell Transplantation Certificate
• Clinical Phytotherapy Application Certificate
• Flow Cytometry Experience Certificate
• E Cell Transplantation Course

Professional Memberships

• Turkish Medical Chamber
• Turkish Hematology Association (Full Member, No: 893)
• Turkish Therapeutic Apheresis Association (Current President)
• Geriatric Hematology Association
• Hematological Oncology Association
• E (European )

Awards & Recognitions

• 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye